Concepedia

Andrew J. Piper-Valillo

AJ

Statistics

Publications

6

Citations

243

H-Index

6

Active since

2017

Affiliations

Lahey Hospital and Medical Center(Current)

University of Massachusetts Chan Medical School

Massachusetts General Hospital

Andrew J. Piper-Valillo is an author at Lahey Hospital and Medical Center specializing in oncology, medicine, and malignant neoplasms.

Publications per year

2017–2024

6

Publications

6

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett et al. · Clinical Cancer Research · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacology +16

Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC)

Andrew J. Piper-Valillo, Jennifer L. Clark, Jose Mercado-Matos et al. · PLoS ONE · 2019 · 31 citations · Full text

Medicine, Cancer Biology, Oncology +17

Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma cells

Jose Mercado-Matos, Jennifer L. Clark, Andrew J. Piper-Valillo et al. · Journal of Biological Chemistry · 2017 · 24 citations · Full text

Life Sciences, Cell Biology, Oncology +17

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC

Allison E.B. Chang, Andrew J. Piper-Valillo, Raymond H. Mak et al. · The Oncologist · 2024 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 6